



Molecular Detection of Vancomycin Resistant Enterococi

Ian Kay BSc(MedSc) PGradDipBiomedSc MBSc
Acting Principal Scientist
Department of Microbiology & Infectious Diseases
PathWest Laboratory Medicine WA
Royal Perth Hospital



VRE

- Members of the genus *Enterococcus* are:

Gram positive Cocci

Catalase : negative

Occur singly or arranged in pairs or short chains

Facultative anaerobes

May be β haemolytic (approximately 30%)

Hydrolyse esculin in the presence of bile salts.



VRE

The enterococci are commensal organisms

Act as opportunistic pathogens particularly in:

- Elderly with serious underlying disease
- Immunocompromised patients with long hospitalisation
- Treated with invasive devices and/or been treated with a broad spectrum antimicrobial.



VRE

E. faecalis is the most common enterococcal species isolated.

E. faecium is the second most common.

Others:

E. gallinarum, *E. avium*, *E. dispar*,



VRE

- Isolation of enterococci can be performed on any blood agar based medium
- They grow well at 35°C – 37°C and do not require a CO₂ environment.



Vancomycin

Vancomycin is a complex glycopeptide antibiotic that was isolated in 1956 from a soil sample containing a newly discovered actinomycete, *Nocardia orientalis*.


Large glycopeptide with a molecular weight of 1,449 daltons (larger than any penicillin, cephalosporin, tetracycline, aminoglycoside or macrolide).

Vancomycin is taken orally or intravenously.



Vancomycin

- Inhibits synthesis of intact peptidoglycan (required for bacterial cell walls)
- Weakened cell wall - the cell undergoes lysis
- Glycopeptides bind to peptidyl-D-alanyl-D-alanine termini of peptidoglycan precursors and prevents transglycosylation and transpeptidation steps of cell wall peptidoglycan synthesis






FIGURE 1. Mechanism of action of vancomycin and mechanisms of vancomycin resistance in enterococci with *vanA*-associated vancomycin resistance. V = vancomycin. From Patel R. Vancomycin-resistant enterococci in solid organ transplantation. *Curr Opin Organ Transplant*. 1999;4:271-280, with permission from Lippincott Williams & Wilkins.




FIGURE 2. The *vanA* operon in Tn1546. From Patel R. Vancomycin-resistant enterococci in solid organ transplantation. *Curr Opin Organ Transplant*. 1999;4:271-280, with permission from Lippincott Williams & Wilkins.

Glycopeptide Resistance in Enterococci

Resistance	Acquired					Intrinsic
Phenotype	VanA	VanB	VanD	VanE	VanG	VanC
MIC (mg/L)						
Vancomycin	64 - >1,000	4 - 1,024	64 - 128	8-32	16	2 - 32
Teicoplanin	16 - 512	0.5 - 1	4 - 64	0.5	0.5	0.5 - 1
Expression	Inducible	Inducible	Constitutive	Inducible	Constitutive	Constitutive/ Inducible
Location	Plasmid Chromosome	Plasmid Chromosome	Chromosome	Chromosome	Chromosome	Chromosome
Transferable	Yes	Yes	No	No	No	No
Most Frequent enterococcal spp	<i>faecium</i> & <i>faecalis</i>					<i>gallinarum</i> <i>casseliflavus</i> <i>flavescens</i>



High Rate of False-Negative Results of the Rectal Swab Culture Method in Detection of Gastrointestinal Colonisation with Vancomycin Resistant Enterococci

D'Agata et al CID 2002

Rectal swab culture

VRE stool density \log_{10} cfu/g stool	samples (n)	VRE detected	Sensitivity %
≥ 2.5	26	15	58
≥ 3.5	19	15	79
≥ 4.5	18	15	83
≥ 5.5	15	14	93
≥ 6.5	13	12	92
≥ 7.5	6	6	100



VANCOMYCIN RESISTANT ENTEROCOCCI (VRE) POLICY

“A major reservoir for VRE is unrecognized colonised patients in hospitals and proximity to a colonised patient is a major risk factor for acquisition. VRE can cause septicaemia in patients with those most at risk being high-risk surgery patients, patients who are immunocompromised and those undergoing dialysis. Transmission of VRE is primarily directly via contaminated hands and clothing of health care workers and indirectly via contaminated equipment and or environment”.



Surveillance Screening of High Risk Wards

- Patients who are direct transfers or have been in a hospital or residential care facility outside WA
- Any patient who has been in a ward with an unisolated VRE carrier during an outbreak
- Any patient who has had VRE isolated on any site
- Intensive Care Unit (ICU)
- High Dependency Area
- Bone Marrow Transplant Unit
- Nephrology Unit
- Haemodialysis Units - monthly
- Geriatric Ward



Enterococcosel Vancomycin Broth (EVB)

- EVB is a selective medium for the cultivation and differentiation of enterococci.
- The broth contains 8mg/L of Vancomycin, esculin and ferric ammonium citrate.
- Any enterococci will hydrolyse the esculin to produce esculetin which in turn reacts with ferric ammonium citrate to form a dark brown or black complex.
- Oxgall (source of bile) and sodium azide are also added which inhibit gram positive and gram negative organisms respectively.



EVB Broths

- Rectal swapped snapped into EVB
- Incubate 35°C for 24 hours for patient
- Incubate 35°C for 36 hours environment swabs
- EVB no colour change – negative
- EVB with a colour change (black) for PCR.

VRE Surveillance Screening Royal Perth Hospital



Enterococcosel™ Broth
Incubate 24hrs 35°C



Negative : **VRE not Isolated**
(approximately 50% of broths)



Positive : **PCR for vanA and vanB**



CULTURE


- EVB positive by PCR
- Subculture

Chromagar with 4mg/L Vancomycin

Chromagar

Blood agar

CHROMagar™ Orientation



- Chromogenic media allows the differentiation of *Enterococcus species* (blue colonies) from other enteric bacteria
 - E. coli* (red colony)
 - Klebsiella sp* (steel blue colony)
 - Proteus* (brown halo colony)
- 24 hours incubation
- Contains the chromogenic substrate x-Gluc which targets β -glucosidase and allows the specific detection of enterococci



24hrs



CULTURE

- Culture
- Dark blue colonies subcultured onto BA for PCR confirmation.

VRE Surveillance Screening Royal Perth Hospital



CLSI Kirby Bauer Disc Diffusion
Incubate and examine 24 hrs at 35°C



Vancomycin 30 μ g disc

Resistant	≤ 14mm zone diameter
Intermediate	15-16mm zone diameter
Sensitive	≥ 17mm zone diameter

“Plates should be held for a full 24 hours and examined using transmitted light. The presence of a haze or any growth within the zone of inhibition indicates resistance. Organisms with an intermediate zone should be tested by an MIC method”




72hrs

VRE Surveillance Screening Royal Perth Hospital



**Vancomycin Etest
Incubate 24hrs 35°C**

Vancomycin



Resistant	≥ 32 mg/L
Intermediate	8-16 mg/L
Sensitive	≤ 4 mg/L

“Plates should be held for a full 24 hours for accurate detection of resistance. For isolates with vancomycin MICs of 8 - 16 mg/L perform biochemical tests for identification”



96hrs



***vanB* Enterococcus faecium Outbreak
Royal Perth Hospital**



Period of the Outbreak

July 2001 - December 2001

Index case

July 2001 (Blood Cultures - ICU)

Number of VRE Cases

**169 colonised
4 infections**

Number of Wards Involved

23 (2 campuses)

vanB *Enterococcus faecium* Outbreak Royal Perth Hospital



vanB *Enterococcus faecium*

Antibiogram

amoxicillin resistant
vancomycin resistant (MIC > 256mg/L)

teicoplanin sensitive (MIC 1.0mg/L)
gentamicin (high level) susceptible

Molecular Characteristics

PCR : *vanB* gene detected
PFGE : distinct CHEF pattern (8 subtypes)
Plasmid profile : distinct and consistent

vanB *Enterococcus faecium* Outbreak
Royal Perth Hospital

Patient and Environmental Screening



Total number of patient screening specimens 19,658

Total number environmental specimens 24,396

Total number positive patients 169



vanB *Enterococcus faecium* Outbreak Royal Perth Hospital

- Direct Culture

Rectal Swabs initially inoculated onto CHROMagar supplemented with 6mg/L vancomycin

VRE Surveillance Screening Royal Perth Hospital



Direct Detection - Enrichment Broth

? VRE

Subculture on BA, Chrom

? Enterococcus species

PCR

Biochemical Identification

Vancomycin and teicoplanin Etest
& disk diffusion

PFGE

Real-Time PCR for the Rapid Detection of *vanA* and *vanB* Genes

Palladino et al *Diagn Microbiol Infect Dis* 2002



Roche Light Cycler

- Rapid Real time PCR in a closed system



Simultaneous detection of *vanA* and *vanB* genes

Hybridisation probes purpose designed using the Roche Applied Science LightCycler Probe Design Software

Reduced potential for amplicon contamination



vanB *Enterococcus faecium* Outbreak Royal Perth Hospital



- 1 *E. durans vanA*
- 4 *E dispar vanA* (4 PFGE types)
- 5 *E. faecalis vanE* (5 PFGE types)
- 10 *E faecium vanA* (7 PFGE)
- 126 *E faecium vanB* (3 PFGE types)
- 1 *E hirae vanA*
- 1 *E species vanA*



vanB *Enterococcus faecium* Outbreak Royal Perth Hospital



Roche LightCycler

- Results available within 1.5hrs
- Significant labour savings were realised
- Potential for direct specimen testing

vanB *Enterococcus faecium* Outbreak Royal Perth Hospital



EVB

- 50% required subculturing
- 38% of subcultured broths grew colonies resembling enterococci
- Very labour intensive

**vanB *Enterococcus faecium* Outbreak
Royal Perth Hospital**



**Rapid Detection of *VanA* and *VanB* Genes Directly from
Clinical Specimens and Enrichment Broths by Real Time
Multiplex PCR**

Palladino et al J Clin Microbiol JCM 2003

Roche Light Cycler

Qiagen QIAamp DNA Stool Mini Kit

Total positive by PCR or Culture : 100 (known positive VRE patients)

	Rectal Swab	Enrichment Broth
Culture	43	75
PCR	45	88



vanB *Enterococcus faecium* Outbreak Royal Perth Hospital



Limitations

- Van gene PCR-positive/culture negative

- low number of cfu of VRE /gm faeces
- non viable VRE
- van gene detected in other genera

Anaerobic clostridia

Bacillus circulans

Bacillus popilliae

Oerskovia lurbata

Arcanobacterium (Corynebacterium) haemolyticum

Staphylococcus aureus

vanB *Enterococcus faecium* Outbreak Royal Perth Hospital



Advantages

- **Greater sensitivity**
enrichment broth culture 75%
enrichment broth PCR 88%
- **Significant labour cost savings**
enrichment broth culture \$15.41/sample (\$8.98 labour)
enrichment broth PCR \$12.93/sample (\$3.37 labour)
- **Earlier clearance of VRE negative swabs**
99% within 28 hours
- **Earlier detection of VRE**
(48 - 72 hours)



Current VRE Detection


Front End Robotics

Currently using Roche MagNA Pure Instrument (reduces RSI and hands on time)

Validating on the LightCycler 480 for higher throughput.

BD GeneOhm™ VanR Assay

Test Procedure Overview




Perianal or Rectal swab



Specimen
Prep



Lysis - DNA
Extraction



Reconstitution



Real-time PCR
Analysis on the
SmartCycler®
Instrument

Site ID	Sample ID	Assay Result	IC Result	Warning/ Error Code
A1	Van A	NEG	NA	
A2	NEG	NEG	PASS	
A3	Van B	Intermittent POS	NA	
A4	Van A et B	Intermittent POS	NA	
A5	NEG	NEG	PASS	
A6	Van B	Intermittent POS	NA	
A7	Van A	POS	NA	
A8	Van A et B	Intermittent POS	NA	
A9	NEG	NEG	PASS	

Definitive On-
screen Results

Results in < 2 hours

Results Interpretation

Sample Type	Instrument-Reported Assay Result	Instrument-Reported IC Result	User Interpretation of Results
Clinical Specimen	NEG	PASS	No <i>vanA</i> or <i>vanB</i> detected
	POS	NA	DNA from <i>vanA</i> resistance gene detected (no <i>vanB</i> detected); probable vancomycin resistant enterococci (VRE).
	Presumptive POS	NA	DNA from <i>vanB</i> resistance gene detected (no <i>vanA</i> detected); presumptive vancomycin resistant enterococci (VRE), <i>vanB</i> resistance gene may be from another organism.
	Positive	NA	DNA from <i>vanA</i> and <i>vanB</i> resistance genes detected; probable vancomycin resistant enterococci (VRE).
	Unresolved	FAIL	Unresolved; inhibitory specimen or reagent failure.
	ND	ND	Not determined due to I-CORE [®] Module failure (with Warning or Error Code ¹).

vanA detected - Probable VRE

vanA and *vanB* detected - Probable VRE


vanB only detected - May be VRE or resistance gene may be from another organism



Results with BD vanR Assay Compared to Culture


VanR Assay

	<i>vanA</i>	<i>vanB</i>	<i>vanA/B</i>	Negative by vanR PCR	Total
vanA Ph	110	3	26	5	144
vanB Ph	0	3	0	0	3
Negative	11	33	2	309	355
Total	121	39	28	314	502

- 
- In summary the *vanR* assay is a good screening assay for VRE in a population of mainly *vanA* colonised patients. However patient samples with *vanB* should be confirmed by another method.

National VRE Network (NaVREN) 2007 to December 2008

Jan Bell



Clinical/screening/institutions

Genotype distribution – ‘clinical’

Species	<i>vanA</i>	<i>vanB</i>	Total	
<i>E. faecium</i>	40	665	705	(82.9%)
<i>E. faecalis</i>	3	135	138	(16.2%)
<i>E. raffinosus</i>	1		1	
<i>Enterococcus spp.</i>	1	5	6	
Total	45	805	850	
	(5.3%)	(94.7%)		

'Clinical' Specimen Types

Species	GType	Urine	Wound	Blood	Other	Sterile cavity	Total
<i>E. faecium</i>	<i>vanA</i>	27	5	6	2		40
	<i>vanB</i>	309	73	150	82	51	665
<i>E. faecalis</i>	<i>vanA</i>	1	1	1			3
	<i>vanB</i>	84	23	8	15	5	135
<i>E. raffinosus</i>	<i>vanA</i>				1		1
Total		421	103	165	104	56	805

52.3%

20.5%



Acknowledgments

**Department of Microbiology and Infectious Diseases
PathWest Laboratory Medicine WA
Royal Perth Hospital**

- **Silvano Palladino**
- **Geoff Coombs**
- **Julie Pearson**
- **Peta Perry**

National VRE Network (NaVREN)

- **Jan Bell**

